Full Transcript Introduction: Psychedelics and the New Era 0:01 We are certainly in a new era in my field, addiction and mental health, and I couldn't be happier. 0:07 You know, since April 17, 2026, when the president signed an executive order aimed at accelerating access to treatments for serious mental illness, 0:16 specifically psychedelics and mainly Ibogaine, I've been flooded with messages, with texts, emails, patient questions, colleagues having debates. 0:26 As Ibogaine finally came to the US, are psychedelics about to replace traditional mental health treatments? 0:32 And patients asking, should I wait for treatment for these therapies instead of starting medication and treatment now? 0:40 Alright, I'm here to talk about psychedelics, about policy and the future of addiction and mental health treatment, what changed and what actually matters. 0:47 So let's start by organizing what's actually happening scientifically, clinically and politically so we can understand the signal through the noise. 0:55 Because there is a big picture shift. 0:57 We're in the middle of a paradigm shift in psychiatry and addiction medicine. 1:01 For decades, most treatments in my field have been daily medications, some long-acting injectables but frequently underutilized, 1:09 incremental symptom reduction, not remission, and long timelines to improvement. 1:14 Now, new medications. 1:16 Some newly approved FDA and also investigational psychedelic-assisted therapies are introducing something different.
Policy Shifts and State-Level Momentum 1:24 rapid symptom change, durable remission effects after limited dosing, and mechanisms rooted in neuroplasticity and in network-level brain changes. 1:34 And now, for the first time, policy is actually catching up with the science. 1:39 This recent executive action is not legalization, but it does signal reduction in barriers to research. 1:46 Really important. 1:47 Potential DEA rescheduling discussions at some point. 1:51 and expansion of right-to-try pathways for treatment-resistant conditions. 1:56 And that matters, but it doesn't mean these treatments are ready for widespread clinical use or ready-for-prime time yet. 2:03 I'm Dr. 2:03 Arvind Podesta. 2:04 I have spent my career treating folks with substance use and addiction and with significant mental health symptoms. 2:10 On this channel, I break down mental-health, neuroscience, and integrative and functional approaches to treatment. 2:16 One integrate approach that I've talked about before, but I am so excited to talk about here, is psychedelic medicine. 2:24 The science, the clinical implications, Now, being a Louisianan and being on our Louisiana Opioid Abatement Task Force, I've got to give props to Louisiana 2:34 because it actually matters right now. 2:36 Here in Louisiana, something big just happened. 2:39 Senate Bill 43, introduced by Patrick McMath, just passed in the State Senate unanimously. 2:47 unanimously. 2:48 That alone should get your attention. 2:50 This bill proposes a regulated psychedelic assisted therapy program housed within the Louisiana Department of Health and funded by opioid settlement dollars. 3:01 this would be focused on treatment resistant PTSD, on opioid use disorder and on severe psychiatric illness.
Psilocybin and MDMA Research Highlights 3:09 And if passed, implementation could begin as early as August 2026, with research centered in academic medical institutions. 3:18 So y'all, this is not fringe anymore. 3:21 This is structured, state-supported medicine in development. 3:25 Now, Louisiana is not alone. 3:27 As of 2026, Oregon and Colorado have fully implemented regulated psychedelic therapy programs for psilocybin, which also has allowed research in those states. 3:38 And New Mexico has passed legislation creating a medical psillocyban access pathway, also opening access to research as well. 3:46 Several other states are actively advancing bills or pilot programs, including research-focused models and PTSD-specific legislation. 3:55 And over a dozen US cities, including Denver and Oakland, have decriminalized certain psychedelics. 4:02 And more than a dozens states are actively considering legislation right now as we speak. 4:07 So seriously, the real deal is that this is no longer theoretical. 4:12 We now have active federal momentum, multiple state-level programs already live, and states like Louisiana building the next wave focused specifically 4:22 on addiction and severe psychiatric illness. 4:25 All right, well, let's talk about the science and what actually works, because we've got to move away from looking at the hype and this new thing, 4:32 but let us look at data. 4:34 So most potent psychedelic thus far is actually psilocybin, and it has the most robust evidence as we are in the research phases. 4:43 There is a large effect size for depression and anxiety. 4:47 Around 70% of patients show a meaningful improvement at week four. 4:51 And also, it is very promising for alcohol and nicotine and other addiction. 4:54 And this is one of the strongest signals that we've seen in psychiatry in decades, certainly in my career.
Ibogaine, Supply, and Sustainability 5:01 Well, another area of research on the horizon is MDMA-assisted therapy, specifically for PTSD. 5:10 After treatment in these studies, about two-thirds of patients no longer meet criteria for PTSD. 5:17 Can you believe that? 5:18 Resolved. 5:20 Effect sizes actually exceed most traditional antidepressant research. 5:25 And I don't know if you know this, but MDMA has already received FDA breakthrough therapy designation. 5:30 But importantly, it's not approved yet. 5:33 It's finalized. 5:35 Well, and then let's talk about ibogaine. 5:37 That was what was on the front page that was mentioned in the executive order. 5:41 And it is the most relevant to opioid addiction. 5:44 Also, really the whole thing is misunderstood because it's very complex. 5:49 This is where my focus is. 5:51 Ibogane is derived from the root bark of a West African shrub called Tabernath iboga, traditionally used in spiritual practices. 6:00 And this matters, for a reason most people aren't thinking about or talking about, because the plant itself is rare. 6:07 It's slow growing. 6:08 Its increasingly difficult to source sustainably. 6:12 As global interest in ibogaine rises, wild harvesting is increasing. 6:16 There's also a massive ecological pressure that's growing, and supply chains are inconsistent and often unregulated. 6:24 So when we talk about scaling ibogaine as a treatment, we're not just talking about it medicinally for treatment. 6:30 We're talking its availability, its sustainability, ethics, and feasibility. 6:36 And that's why a major focus of research is currently finding a synthetic production pathway using biotechnological approaches for the enzymatic pathways 6:47 that iblogaine works on. 6:48 Because if this becomes a legitimate treatment, we can't rely on stripping a rare plant from Central and West Africa to meet a global demand.
Ibogaine Safety, Risks, and Synthetic Alternatives 6:57 Now pharmacologically, Ibogaine is very different from other psychedelics. 7:01 It's what we call polypharmacologic. 7:04 it works across multiple systems.It works on the opioid receptors.it works in the NMDA and glutamate signaling pathways, 7:12 on dopamine reward pathways and on serotonin transport systems and honestly this multitude of efficacy is part of the beauty of whole plant medicine. 7:22 But I and many others have concern about using the whole plants in this case. 7:27 Clinically, ibogaine works imparting rapid reduction in opioid withdrawal symptoms, significant decreases in cravings, and the effects might last weeks 7:37 to months after just a single administration. 7:40 Some studies actually show 50% reduction craving and many patients with minimal withdrawal within 48 hours. 7:47 And that's not something we've seen in standard treatments. 7:51 But there are risks, real risks. 7:53 And this requires medical caution. 7:55 Because ibogaine, it's not a gentle or low-risk intervention. 8:00 It actually carries significant medical concerns, such as cardiac electric changes called QT prolongation, risk of fatal arrhythmias, 8:10 liver and neurological toxicity in some. 8:13 In some of the studies, up to half of patients had significant Q-T interval changes. 8:19 And yes, sadly, there have been documented deaths. 8:22 But there's yet another level of risk that's often overlooked, and it actually ties back to the plant itself, because ibogaine is, 8:31 as you heard, very difficult to source. 8:33 And it's also extracted in unregulated environments and distributed through inconsistent global supply chains. 8:40 So purity and dosing can vary significantly outside of controlled settings. 8:45 And that means that patients are not just exposed to the pharmacological risks of ibogaine, they may also be exposed too toxic contaminants, 8:54 to inaccurate dosings, and they might have lack of medical grade formulations given to them. 9:01 And this is where one of the strongest arguments for the legislation is something that we are super excited about because we need the research. 9:08 We need pharmaceutical-grade synthesis, standardized production, regulated clinical environments. 9:15 And, this where the science is evolving. 9:17 Researchers are working on the fully synthetic ibogaine.
Current Standards of Care and Clinical Caution 9:22 safer analogs that reduce cardiac risk, control delivery models with cardiac monitoring. 9:28 Because if Ibogaine or Iboganelike treatments are going to be used in mainstream medicine, they must meet the same standards as any other medicine. 9:36 Consistent, safe, and reproducible. 9:40 So when we talk about Ibogaene, we're really talking about three simultaneous challenges. 9:45 clinical efficacy, which is quite promising, medical safety, not something to sneeze at, and sustainability and ethical production, 9:54 absolutely essential for the future. 9:57 Well, this excitement is justified for sure. 10:01 And there's a lot of momentum. 10:03 So with Ibogaine, we're seeing rapid interruption of addictive patterns, actual neuroplastic changes that may reset the reward pathways, 10:12 and psychological experiences that facilitate meaningful and meaning-making changes and behavioral changes. 10:19 The field and research is heading towards safer and targeted versions of the powerful mechanisms of ibogaine, but hopefully in a semi-synthetic or a synthetic 10:30 or sustainable form. 10:32 And this is where all of this fits into real clinical practice. 10:36 Now, today, as we speak for opioid use disorder, the gold standards remain psychosocial support and harm reduction strategies and then medications for 10:45 opiod use disorders such as buprenorphine, methadone, and naltrexone. 10:49 Of course, always naloxone as well, co-prescribed. 10:53 He saved lives every day. 10:55 And this is what I use and what i teach and talk about in my book, Hooked. 10:59 Also, psychedelic therapies, including ibogaine, are super promising in this space. 11:05 potentially transformative, but still emerging and investigational. 11:10 The biggest mistake I'm seeing right now is patients, providers, and the general community thinking, I'll just wait for psychedelics because they're on 11:18 their way, right? 11:19 Be sure though that delay can be dangerous. 11:23 So yes, we are entering a new era in psychiatry and addiction treatment. 11:28 That federal policy is shifting. 11:30 States like Louisiana are stepping forward. 11:32 And yes the science is very strong and stronger than it ever has been. 11:38 Well, I have to say some people are actually calling it the end of the beginning because research on this subject actually began over 40 years ago in the 1980s. 11:50 But we're still in the translational phase, moving from promising data to safe, scalable care. 11:56 Ibogaine and other psychedelics may become powerful tools in our toolbox, but not yet. 12:02 And they're not replacements. 12:03 They are potential additions to a much larger evidence-based system of care, and if we do this right, carefully, scientifically and ethically, 12:13 we may finally start closing the gap for patients with the most severe and treatment-resistant conditions. 12:20 If you want a deeper breakdown of how abogaine actually works in the brain and why it's so different from other psychedelics, 12:26 I'll cover that in another video. 12:29 Thanks for staying curious and checking out what's on the horizon.
Comments